<DOC>
	<DOCNO>NCT00777114</DOCNO>
	<brief_summary>This multi-center , Phase I , dose-escalation study bortezomib combination 131I-tositumomab patient relapse non-Hodgkin 's lymphoma . Bortezomib administer patient twice weekly , first dose give two day prior treatment dose 131I-tositumomab , second dose two day RIT total 5 dos . Patients enrol undergo standard stag study , include history , physical examination , complete blood count , serum chemistry LDH , TSH , HAMA , iliac crest bone marrow biopsy , CT scan chest , abdomen pelvis . All patient provide write informed consent . Bortezomib evaluate 4 dose level ( 0.30 mg/m2 , 0.60 mg/m2 , 0.90 mg/m2 , 1.2 mg/m2 ) 131I-tositumomab 2 dose level ( 50 cGy 75 cGy TBD ) . Bortezomib administrate day prior 131I-tositumomab twice weekly thereafter 4 dos order provide proteasome inhibition throughout period 131I-tositumomab activity . The intention use 131I-tositumomab full dose possible . Therefore , 50cGy dose use low dose bortezomib case unexpected toxicity combination . Dose level follow : 1 . 0.30mg/m2 bortezomib 50cGy 131I-tositumomab , 2 . 0.30 mg/m2 bortezomib 75 cGy 131I-tositumomab , 3 . 0.60 mg/m2 bortezomib 75 cGy 131I-tositumomab , 4 . 0.90 mg/m2 bortezomib 75 cGy 131I-tositumomab , 5 . 1.2 mg/m2 bortezomib 75 cGy 131I-tositumomab .</brief_summary>
	<brief_title>Phase 1 Study Radiosensitization Using Bortezomib Relapsed Non-Hodgkin 's Lymphoma Patients Receiving Radioimmunotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients must histologically prove relapsed refractory MCL , DLBCL include subtypes mediastinal large B cell , centroblastic , immunoblastic , T cell rich B cell anaplastic large B cell lymphoma , low grade B cell NHL . Patients must receive prior systemic therapy lymphoma . Age &gt; 18 year . Life expectancy great 12 week Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Ability understand willingness sign write informed consent document Patients may receive investigational agent . Patients know brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . History allergic reaction attribute compound similar chemical biologic composition bortezomib boron . Previous radiation therapy maximum tissue tolerance site . Previous autologous allogeneic stem cell transplantation . Involvement bone marrow &gt; 25 % lymphoma . Known involvement central nervous system lymphoma . 17 Significant organ dysfunction , include hematologic ( absolute neutrophil count &lt; 1500 , platelets &lt; 150,000 ) . ECOG performance status &gt; 2 . Uncontrolled illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . HIV infection . Patient calculate measured creatinine clearance &lt; 20 mL/minute within 14 day enrollment . Patient ≥Grade 2 peripheral neuropathy within 14 day enrollment . Myocardial infarction within 3 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( see section 8.4 ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant . Patient hypersensitivity bortezomib , boron mannitol . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>relapse non-Hodgkin 's lymphoma</keyword>
</DOC>